Moolec Science (MLEC) Net Margin (2023 - 2024)

Moolec Science's (MLEC) quarterly Net Margin came in at 70.58% in Q4 2024, up 82405.0% year-on-year from N/an in Q1 2024, and up 44.25% quarter-over-quarter from 126.62% in Q3 2024.

Moolec Science (MLEC) Net Margin (2023 - 2024) Analysis & Trends

Moolec Science has disclosed Net Margin across 2 years of filings, most recently posting 70.58% for Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.82%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 34.53%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Moolec Science 6.98 Bn 6.98 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -70.58%
Sep 30, 2024 -126.62%
Mar 31, 2024 -54.43%
Dec 31, 2023 -894.63%
Sep 30, 2023 -116.18%